Alsakarneh, S., Ta’ani, O. A., Aburumman, R., Mikhail, I., Hashash, J. G., & Farraye, F. A. (2025). Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study. Wiley. https://doi.org/10.1111/apt.70139
Cita Chicago Style (17a ed.)Alsakarneh, Saqr, Omar Al Ta’ani, Razan Aburumman, Inas Mikhail, Jana G. Hashash, y Francis A. Farraye. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study. Wiley, 2025. https://doi.org/10.1111/apt.70139.
Cita MLA (9a ed.)Alsakarneh, Saqr, et al. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL‐17A Inhibitors: A Population‐Based Study. Wiley, 2025. https://doi.org/10.1111/apt.70139.